Active Management of the Third Stage of Postpartum Hemorrhage

SOGC CLINICAL PRACTICE GUIDELINE
SOGC CLINICAL PRACTICE
GUIDELINE
No. 235 October
2009 (Replaces No. 88, April 2000)
Active Management of the Third Stage of
Labour: Prevention and Treatment of
Postpartum Hemorrhage
This Clinical Practice Guideline has been prepared by the Clinical
Practice Obstetrics Committee and approved by the Executive and
Council of the Society of Obstetricians and Gynaecologists of
Canada.
PRINCIPAL AUTHOR
be relevant. Each full-text article was critically appraised with use
of the Jadad Scale and the levels of evidence definitions of the
Canadian Task Force on Preventive Health Care.
Values: The quality of evidence was rated with use of the criteria
described by the Canadian Task Force on Preventive Health Care.
Dean Leduc, MD, Ottawa ON
Sponsor: The Society of Obstetricians and Gynaecologists of
Canada.
Vyta Senikas, MD, Ottawa ON
Recommendations
André B. Lalonde, MD, Ottawa ON
Prevention of Postpartum Hemorrhage
CLINICAL PRACTICE OBSTETRICS COMMITTEE
1. Active management of the third stage of labour (AMTSL) reduces
the risk of PPH and should be offered and recommended to all
women. (I-A)
Dean Leduc (Chair), MD, Ottawa ON
Charlotte Ballerman, MD, Edmonton AB
Anne Biringer, MD, Toronto ON
Martina Delaney, MD, St. John’s NL
Louise Duperron, MD, Montreal QC
Isabelle Girard, MD, Montreal QC
Donna Jones, MD, Calgary AB
Lily Shek-Yun Lee, MD, Vancouver BC
Debra Shepherd, MD, Regina SK
Kathleen Wilson, RM, Ilderton ON
Disclosure statements have been received from all members of the
committee.
Abstract
Objective: To review the clinical aspects of postpartum hemorrhage
(PPH) and provide guidelines to assist clinicians in the prevention
and management of PPH. These guidelines are an update from
the previous Society of Obstetricians and Gynaecologists of
Canada (SOGC) clinical practice guideline on PPH, published in
April 2000.
Evidence: Medline, PubMed, the Cochrane Database of Systematic
Reviews, ACP Journal Club, and BMJ Clinical Evidence were
searched for relevant articles, with concentration on randomized
controlled trials (RCTs), systematic reviews, and clinical practice
guidelines published between 1995 and 2007. Each article was
screened for relevance and the full text acquired if determined to
Key Words: Prevention, hemorrhage, obstetrics, obstetric
hemorrhage
2. Oxytocin (10 IU), administered intramuscularly, is the preferred
medication and route for the prevention of PPH in low-risk vaginal
deliveries. Care providers should administer this medication after
delivery of the anterior shoulder. (I-A)
3. Intravenous infusion of oxytocin (20 to 40 IU in 1000 mL, 150 mL
per hour) is an acceptable alternative for AMTSL. (I-B)
4. An IV bolus of oxytocin, 5 to 10 IU (given over 1 to 2 minutes), can
be used for PPH prevention after vaginal birth but is not
recommended at this time with elective Caesarean section. (II-B)
5. Ergonovine can be used for prevention of PPH but may be
considered second choice to oxytocin owing to the greater risk of
maternal adverse effects and of the need for manual removal of a
retained placenta. Ergonovine is contraindicated in patients with
hypertension. (I-A)
6. Carbetocin, 100 mg given as an IV bolus over 1 minute, should be
used instead of continuous oxytocin infusion in elective Caesarean
section for the prevention of PPH and to decrease the need for
therapeutic uterotonics. (I-B)
7. For women delivering vaginally with 1 risk factor for PPH,
carbetocin 100 mg IM decreases the need for uterine massage to
prevent PPH when compared with continuous infusion of oxytocin. (I-B)
8. Ergonovine, 0.2 mg IM, and misoprostol, 600 to 800 mg given by
the oral, sublingual, or rectal route, may be offered as alternatives
in vaginal deliveries when oxytocin is not available. (II-1B)
9. Whenever possible, delaying cord clamping by at least 60 seconds
is preferred to clamping earlier in premature newborns (< 37 weeks’
gestation) since there is less intraventricular hemorrhage and less
need for transfusion in those with late clamping. (I-A)
10. For term newborns, the possible increased risk of neonatal
jaundice requiring phototherapy must be weighed against the
This document reflects emerging clinical and scientific advances on the date issued and is subject to change. The information
should not be construed as dictating an exclusive course of treatment or procedure to be followed. Local institutions can dictate
amendments to these opinions. They should be well documented if modified at the local level. None of these contents may be
reproduced in any form without prior written permission of the SOGC.
980
l OCTOBER JOGC OCTOBRE 2009
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
Table 1. Key to evidence statements and grading of recommendations, using the ranking of the
Canadian Task Force on Preventive Health Care
Quality of Evidence Assessment*
Classification of Recommendations†
I:
A. There is good evidence to recommend the clinical preventive
action
Evidence obtained from at least one properly randomized
controlled trial
II-1: Evidence from well-designed controlled trials without
randomization
B. There is fair evidence to recommend the clinical preventive
action
II-2: Evidence from well-designed cohort (prospective or
retrospective) or case-control studies, preferably from more
than one centre or research group
C. The existing evidence is conflicting and does not allow to
make a recommendation for or against use of the clinical
preventive action; however, other factors may influence
decision-making
II-3: Evidence obtained from comparisons between times or
places with or without the intervention. Dramatic results in
uncontrolled experiments (such as the results of treatment
with penicillin in the 1940s) could also be included in this
category
III: Opinions of respected authorities, based on clinical
experience, descriptive studies, or reports of expert
committees
D. There is fair evidence to recommend against the clinical
preventive action
E. There is good evidence to recommend against the clinical
preventive action
L. There is insufficient evidence (in quantity or quality) to make
a recommendation; however, other factors may influence
decision-making
*The quality of evidence reported in these guidelines has been adapted from The Evaluation of Evidence criteria described in the Canadian Task Force
on Preventive Health Care.54
†Recommendations included in these guidelines have been adapted from the Classification of Recommendations criteria described in the The Canadian
Task Force on Preventive Health Care.54
physiological benefit of greater hemoglobin and iron levels up to
6 months of age conferred by delayed cord clamping. (I-C)
11. There is no evidence that, in an uncomplicated delivery without
bleeding, interventions to accelerate delivery of the placenta
before the traditional 30 to 45 minutes will reduce the risk of PPH.
(II-2C)
12. Placental cord drainage cannot be recommended as a routine
practice since the evidence for a reduction in the duration of the
third stage of labour is limited to women who did not receive
oxytocin as part of the management of the third stage. There is no
evidence that this intervention prevents PPH. (II-1C)
13. Intraumbilical cord injection of misoprostol (800 mg) or oxytocin
(10 to 30 IU) can be considered as an alternative intervention
before manual removal of the placenta. (II-2C)
Treatment of PPH
14. For blood loss estimation, clinicians should use clinical markers
(signs and symptoms) rather than a visual estimation. (III-B)
15. Management of ongoing PPH requires a multidisciplinary
approach that involves maintaining hemodynamic stability while
simultaneously identifying and treating the cause of blood loss. (III-C)
16. All obstetric units should have a regularly checked PPH
emergency equipment tray containing appropriate equipment. (II-2B)
17. Evidence for the benefit of recombinant activated factor VII has
been gathered from very few cases of massive PPH. Therefore
this agent cannot be recommended as part of routine practice. (II-3L)
18. Uterine tamponade can be an efficient and effective intervention to
temporarily control active PPH due to uterine atony that has not
responded to medical therapy. (III-L)
19. Surgical techniques such as ligation of the internal iliac artery,
compression sutures, and hysterectomy should be used for the
management of intractable PPH unresponsive to medical
therapy. (III-B)
Recommendations were quantified using the evaluation of
evidence guidelines developed by the Canadian Task Force on
Preventive Health Care (Table 1).
J Obstet Gynaecol Can 2009;31(10):980–993
INTRODUCTION
ostpartum hemorrhage is the leading cause of maternal
death worldwide, with an estimated mortality rate of
140 000 per year, or 1 maternal death every 4 minutes.1 PPH
occurs in 5% of all deliveries and is responsible for a major
part of maternal mortality.2,3 The majority of these deaths
occur within 4 hours of delivery, which indicates that they
are a consequence of the third stage of labour.4,5 Nonfatal
PPH results in further interventions, iron deficiency anemia, pituitary infarction (Sheehan’s syndrome) with associated poor lactation, exposure to blood products,
coagulopathy, and organ damage with associated
hypotension and shock.
P
Since all parturient women are at risk for PPH, care providers need to possess the knowledge and skills to practise
active management of the third stage of labour to prevent
PPH and to recognize, assess, and treat excessive blood
loss.
ABBREVIATIONS
AMTSL active management of the third stage of labour
PPH
postpartum hemorrhage
RCT
randomized controlled trial
DEFINITION OF PPH
Primary PPH is defined as excessive bleeding that occurs in
the first 24 hours after delivery.
OCTOBER JOGC OCTOBRE 2009 l
981
SOGC CLINICAL PRACTICE GUIDELINE
Table 2. Signs and symptoms of shock resulting from
blood loss
Degree of shock
Blood loss
< 20%
Mild
Moderate
Severe
20% to 40%
> 40%
Signs and symptoms
Diaphoresis
Increased capillary refilling
Cool extremities
Anxiety
Above plus
Tachycardia
Tachypnea
Postural hypotension
Oliguria
Above plus
Hypotension
Agitation/confusion
Hemodynamic instability
Traditionally the definition of PPH has been blood loss in
excess of 500 mL after vaginal delivery and in excess of
1000 mL after abdominal delivery. For clinical purposes,
any blood loss that has the potential to produce
hemodynamic instability should be considered PPH. The
amount of blood loss required to cause hemodynamic instability will depend on the pre-existing condition of the
woman. Hemodynamic compromise is more likely to occur
in conditions such as anemia (e.g., iron deficiency,
thalassemia) or volume-contracted states (e.g., dehydration,
gestational hypertension with proteinuria).
Hypovolemic Shock6
Excessive bleeding, or hemorrhage, results in net loss of
intravascular volume and decreased oxygen delivery to tissues and organs. Physiological compensatory mechanisms
such as reflex tachycardia, peripheral vasoconstriction, and
increased myocardial contractility help to maintain tissue
perfusion. Increasing blood loss results in circulatory collapse, end-organ damage, and eventual death.
Ideally, care providers should be able to assess the amount
of blood loss in order to estimate the volume of fluid that
needs to be replaced. However, research has shown that clinicians often underestimate the actual loss.7 The signs and
symptoms listed in Table 2 should be used at the bedside to
evaluate the amount of blood loss since, in general, the
degree of shock parallels the amount of blood loss that
results in these clinical markers.6
Etiology of PPH
In regard to the underlying causes of PPH, it may be helpful
to think in terms of the 4 Ts:
• Tone: uterine atony, distended bladder
• Tissue: retained placenta and clots
• Trauma: vaginal, cervical, or uterine injury
• Thrombin: coagulopathy (pre-existing or acquired)
982
l OCTOBER JOGC OCTOBRE 2009
The most common and important cause of PPH is uterine
atony. The primary protective mechanism for immediate
hemostasis after delivery is myometrial contraction causing
occlusion of uterine blood vessels, the so-called living ligatures of the uterus. Thus blood flow from the vascular
space to the uterine cavity via the myometrium is impeded.
Maternity care providers should recognize the risk factors
for PPH due to the 4 Ts, as listed in Table 3, and take appropriate action.
PREVENTION OF PPH
AMTSL involves interventions to assist in expulsion of the
placenta with the intention to prevent or decrease blood
loss. Interventions include use of uterotonics, clamping of
the umbilical cord, and controlled traction of the cord. In
contrast, with expectant, or physiological, management,
spontaneous delivery of the placenta is allowed, with subsequent intervention, if necessary, that involves uterine
massage and use of uterotonics.
Prendiville and colleagues’ meta-analysis8 demonstrated the
benefits of AMTSL to prevent and reduce PPH after vaginal delivery for women at low risk of PPH. Studies included
in the meta-analysis had design methods that involved routine use of uterotonics after delivery of the newborn and
before delivery of the placenta, early cord clamping, and
controlled cord traction. The primary goal of these interventions was to assist placental delivery, thereby allowing
the uterus to contract and reduce blood flow across the
myometrium.
The meta-analysis concluded that active compared with
expectant management significantly reduced the risk in all
areas, including mild PPH (estimated blood loss > 500 mL;
OR 0.38; 95% CI 0.32 to 0.46), severe PPH (estimated
blood loss > 1000 mL; OR 0.32; 95% CI 0.21 to 0.50), low
postpartum hemoglobin level (< 9 g/dL; OR 0.38; 95% CI
0.27 to 0.53), need for transfusion (OR 0.33; 95% CI 0.21 to
0.52), and need for additional uterotonic medication (OR
0.17; 95% CI 0.14 to 0.21). There was no difference in the
incidence of retained placenta or management of this
complication by manual or surgical removal. There was
significantly more nausea and hypertension in the actively
managed group given ergonovine (OR 1.83; 95% CI 1.51
to 2.23).
A review of the data resulted in a joint statement in 2004 by
the International Confederation of Midwives and International Federation of Gynaecologists and Obstetricians
endorsing the need for all deliveries to be attended by a
caregiver trained in AMTSL, which should include routine
use of uterotonics, controlled cord traction, and uterine
massage.9 Delaying cord clamping by 1 to 3 minutes was
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
Table 3. Risk factors for postpartum hemorrhage (PPH)
Etiologic category and process
Tone: abnormalities of uterine contraction
Overdistension of uterus
Uterine muscle exhaustion
Intra-amniotic infection
Functional/anatomic distortion of uterus
Uterine-relaxing medications
Bladder distension, which may prevent
uterine contraction 4
Tissue: retained
Retained products of conception
Abnormal placentation
Retained cotyledon or succenturiate lobe
Retained blood clots
Trauma: of the genital tract
Lacerations of the cervix, vagina, or perineum
Extensions, lacerations at cesarean section
Uterine rupture
Uterine inversion
Thrombin: abnormalities of coagulation
Pre-existing states
Clinical risk factors
Polyhydramnios
Multiple gestation
Macrosomia
Rapid labour
Prolonged labour
High parity
Oxytocin use
Fever
Prolonged rupture of membranes
Fibroids
Placenta previa
Uterine anomalies
Halogenated anesthetics
Nitroglycerin
Incomplete placenta at delivery
Previous uterine surgery
High parity
Abnormal placenta seen on ultrasonography
Atonic uterus
Precipitous delivery
Operative delivery
Malposition
Deep engagement
Previous uterine surgery
High parity
Fundal placenta
Excessive cord traction
History of hereditary coagulopathies or liver disease
Hemophilia A
Von Willebrand’s disease
History of previous PPH
Acquired in pregnancy
Idiopathic thrombocytopenic purpura
Bruising, elevated blood pressure
Thrombocytopenia with preeclampsia
Disseminated intravascular coagulation
Gestational hypertensive disorder of pregnancy
with adverse conditions
Elevated blood pressure
a) Dead fetus in utero
Fetal demise
b) Severe infection
Fever, neutrophilia/neutropenia
c) Abruption
Antepartum hemorrhage
d) Amniotic fluid embolus
Therapeutic anticoagulation
Sudden collapse
History of thrombotic disease
favoured over early cord clamping to reduce anemia in the
newborn.
1. Active management should be offered to all women
by skilled care providers.
A similar review of the literature in 2006 by the World
Health Organization10 highlighted the most common cause
of PPH as uterine atony and the fact that most women with
PPH have no identifiable risk factors. The review resulted
in several recommendations to minimize maternal morbidity and mortality rates.
2. Skilled attendants should offer uterotonics (oxytocin
preferred over ergonovine, misoprostol, and
carboprost) to prevent PPH.
3. Early cord clamping is recommended only when the
newborn needs to be resuscitated.
OCTOBER JOGC OCTOBRE 2009 l
983
SOGC CLINICAL PRACTICE GUIDELINE
4. Despite the lack of evidence to support cord traction,
this practice should be continued as part of active
management.
Uterotonics
During the third stage of labour the muscles of the uterus
contract downward, causing constriction of the blood vessels that pass through the uterine wall to the placental surface and stopping the flow of blood. This action also causes
the placenta to separate from the uterine wall. The absence
of uterine contractions, clinically defined as atony, may
result in excessive blood loss. Uterotonics promote uterine
contractions to prevent atony and speed delivery of the
placenta.
The uterotonic agents include oxytocin, ergonovine,
carbetocin, misoprostol, and Syntometrine (a combination
of ergonovine and oxytocin, unavailable in Canada).
Oxytocin and ergonovine
The 1997 Abu Dhabi study11 included in Prendiville and
colleagues’meta-analysis8 randomly allocated low-risk
women who delivered vaginally to receive either 10 IU of
oxytocin IM with delivery of the anterior shoulder followed
by controlled cord traction upon signs of placental separation or minimal intervention. The results revealed a benefit
for the oxytocin group: a lower incidence of blood loss
> 500 mL (OR 0.50; CI 0.34 to 0.73) and > 1000 mL (OR
0.22; CI 0.08 to 0.57), fewer retained placentas (OR 0.31; CI
0.15 to 0.63), and less need for additional uterotonics (OR
0.44; CI 0.24 to 0.78).
A 2004 Cochrane Review12 compared the efficacy of
Syntometrine and oxytocin alone, both administered IM, in
AMTSL. The results showed a small benefit for
Syntometrine in preventing blood loss > 500 mL (OR 0.82;
95% CI 0.71 to 0.95) but no difference in preventing losses
> 1000 mL. The group receiving Syntometrine were more
likely to have elevated diastolic blood pressure (OR 2.40;
95% CI 1.58 to 3.64), nausea (OR 4.07; 95% CI 3.43 to
4.84), and vomiting (OR 4.92; 95% CI 4.03 to 6.00). The
authors favoured oxytocin alone on the basis of the lower
incidence of maternal side effects.
A 2008 meta-analysis13 included 14 studies assessing the
benefits of oxytocin in AMTSL for vaginal deliveries. Seven
trials comparing oxytocin and no uterotonics found a lower
incidence of blood loss > 500 mL (RR 0.50; 95% CI 0.43 to
0.59) and less need for therapeutic oxytocin (RR 0.5; 95%
CI 0.39 to 0.64) in the groups receiving oxytocin. Six trials
found no difference between the results with oxytocin and
ergonovine except that the groups receiving oxytocin had
fewer manual removals of the placenta (RR 0.57; 95% CI
0.41 to 0.79) and a tendency to a lower incidence of raised
blood pressure (RR 0.53; 95% CI 0.19 to 1.52) than the
984
l OCTOBER JOGC OCTOBRE 2009
groups receiving ergonovine. Five trials showed little evidence of a synergistic effect of adding oxytocin to
ergonovine versus ergonovine alone.
One double-blind randomized controlled trial14 compared
the efficacy of 10 IU of oxytocin in saline solution with
saline solution alone in cephalic vaginal deliveries in
low-risk women. The oxytocin group had a lower mean
blood loss (407 vs. 527 mL), a lower incidence of blood loss
> 800 mL (8.8% vs. 5.2%), and a lower rate of use of additional ergonovine (3.5% vs. 2.3%). Another double-blind
RCT15 found no difference in the incidence of PPH among
women with low-risk vaginal deliveries given an IV bolus of
oxytocin (20 IU in 500 mL of crystalloid) before or after
delivery of the placenta.
The use of a slow IV bolus in management of the third stage
of labour has been adopted as standard practice although
there is little supporting evidence in the literature. The
Dublin trial16 was the only study in Prendiville and
colleagues’meta-analysis8 in which a uterotonic
(Syntometrine) was administered IV; the result was a lower
incidence of PPH but more retained placentas.
There has been concern about the safety of such rapid
administration of oxytocin in the third stage, although
99 women given 10 IU in an IV push after vaginal delivery
did not have significant hemodynamic effects. The study,
however, was underpowered to demonstrate a reduction in
the incidence of PPH.17
For women undergoing elective Caesarean section, recent
studies have demonstrated adverse maternal effects of an
oxytocin IV bolus. One double-blind RCT found
hemodynamic changes in 30 patients given 5 IU IV over 30
seconds compared with women who received the same
dose over 5 minutes.18 In another double-blind RCT, 40
patients given 10 IU of oxytocin as an IV bolus manifested
electrocardiographic changes consistent with myocardial
ischemia when compared with pregnant women who
received 0.2 mg of ergonovine and nonpregnant women;
the effect was transient, with onset at 1 minute and resolution by 5 minutes after exposure to oxytocin.19 These studies suggest a potential maternal effect of the rapid administration (within 30 seconds) of oxytocin, and it may be
dose-related.
Oxytocin given as part of AMTSL has been shown to
reduce the need for manual removal of a retained placenta
compared with expectant management.8,13 The greater need
for manual removal noted in the Dublin trial16 was attributed to the use of Syntometrine as an IV bolus. A 2001
Cochrane review13 of prophylactic IM oxytocin use during
the third stage of labour demonstrated a significantly
reduced need for manual removal of the placenta compared
with ergometrine use (RR 0.57; 95% CI 0.41 to 0.79).
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
Recommendations
Recommendations were quantified using the evaluation of
evidence guidelines developed by the Canadian Task Force
on Preventive Health Care (Table 1).
1. AMTSL reduces the risk of PPH and should be offered
and recommended to all women. (I-A)
2. Oxytocin (10 IU), administered intramuscularly, is the
preferred medication and route for the prevention of
PPH in low-risk vaginal deliveries. Care providers
should administer this medication after delivery of the
anterior shoulder. (I-A)
3. Intravenous infusion of oxytocin (20 to 40 IU in 1000 mL,
150 mL per hour) is an acceptable alternative for
AMTSL. (I-B)
4. An IV bolus of oxytocin, 5 to 10 IU (given over 1 to
2 minutes), can be used for PPH prevention after vaginal
birth but is not recommended at this time with elective
Caesarean section. (II-B)
5. Ergonovine can be used for prevention of PPH but may
be considered second choice to oxytocin owing to the
greater risk of maternal adverse effects and of the need
for manual removal of a retained placenta. Ergonovine is
contraindicated in patients with hypertension. (I-A)
Carbetocin
Carbetocin is a long-acting oxytocin studied by Dansereau
et al.,20 who performed an RCT comparing the incidence of
PPH in women undergoing elective Caesarean section who
received either carbetocin as a 100-mg IV bolus or oxytocin
as a continuous infusion for 8 hours (25 IU of oxytocin in
1000 mL of Ringer’s lactate, 125 mL per hour). The
carbetocin group had a decreased incidence of PPH and of
the need for therapeutic oxytocics (4.7% vs. 10.1%; P <
0.05). The recommended dose of carbetocin is 100 mg given
either IM or slowly (over 1 minute), the pharmacokinetics
of the 2 administration routes being almost the same.21
Boucher and colleagues’ double-blind 2003 RCT22 demonstrated that women with at least 1 risk factor for PPH who
were given carbetocin (100 mg IM) immediately after placental delivery were less likely to required uterine massage
as a uterotonic intervention than those given a continuous
infusion of oxytocin over 2 hours: 43.4% of women in the
carbocetin group (36/83 [43.4%]; 95%CI, 32.7% to 54%
vs. 48/77 [62.3%] of women in the oxytocin group; 95%
CI, 51.5% to 73.2%) required the massage (P = 0.02). There
was no difference in the requirement for additional
uterotonic medication (i.e., oxytocin, ergonovine), estimated blood loss, or difference in hemoglobin level before
and after vaginal delivery. There was no significant benefit
of carbetocin over oxytocin in the prevention of PPH. The
authors commented on the advantage of IM intervention in
a setting where IV treatment is unavailable.
A 2007 Cochrane Review23 included 4 RCTs that compared
carbetocin with oxytocin for prevention of PPH. The
results were consistent with the results of the trials conducted by Dansereau and Boucher and their colleagues.20,22
Since none of the trials included low-risk women, there was
insufficient evidence that 100 mg of carbetocin given IV is
as effective as oxytocin in the prevention of PPH in low-risk
vaginal deliveries.
An RCT by Leung et al.24 compared IM administration of
carbetocin and Syntometrine in AMTSL for singleton vaginal deliveries after 34 weeks. The results showed no difference in the incidence of a low hemoglobin level, blood loss
> 500 mL, retained placenta, or use of additional uterotonic
agents. Carbetocin recipients had less nausea (RR 0.18;
95%CI 0.04 to 0.78), vomiting (RR 0.1; 95% CI 0.01 to
0.74), and hypertension 30 minutes (0 vs. 8 cases, P < 0.01)
and 60 minutes (0 vs. 6 cases, P < 0.05) after delivery. There
was a higher incidence of maternal tachycardia (RR 1.68;
95% CI 1.03 to 3.57) in the carbetocin group.
We did not identify any published reports of trials comparing oxytocin and carbetocin, each administered IM for
AMTSL, in low-risk term vaginal deliveries.
Recommendations
6. Carbetocin, 100 mg given as an IV bolus over 1 minute,
should be used instead of continuous oxytocin infusion
in elective Caesarean section for the prevention of PPH
and to decrease the need for therapeutic uterotonics. (I-B)
7. For women delivering vaginally with 1 risk factor for
PPH, carbetocin 100 mg IM decreases the need for uterine massage to prevent PPH when compared with continuous infusion of oxytocin. (I-B)
Misoprostol
Misoprostol is a prostaglandin that has generated considerable interest as an effective uterotonic agent owing to its
ease of administration, safety profile, cost, and ease of storage. The first study of misoprostol as a uterotonic agent was
an uncontrolled prospective study for prevention of PPH.25
A systematic review26 that analyzed the pharmacokinetics of
misoprostol concluded the following:
• There is a shorter time to peak concentration with oral
and sublingual administration than with vaginal or
rectal administration.
• Sublingual administration results in the most rapid
onset of effects and the highest peak concentration.
• The initial increase in tonus is more pronounced after
oral than after vaginal administration.
OCTOBER JOGC OCTOBRE 2009 l
985
SOGC CLINICAL PRACTICE GUIDELINE
• The effects have a slower onset but longer duration
with rectal and vaginal routes than with oral and
sublingual routes.
• Pyrexia is more common when the dose exceeds
600 mg.
There have been 3 systematic reviews of the use of
misoprostol for the prevention of PPH.27–29 The WHO
multicentre trial30 and the Cochrane review27 suggested that
the observed lesser efficacy of misoprostol compared with
injectable uterotonics may be due to the later achievement
of peak plasma levels with oral and sublingual administration of misoprostol: 30 minutes versus 1 to 2 minutes for
IM or IV administration of oxytocin. All of the reviews concluded that misoprostol was not as effective as oxytocin for
the prevention of PPH and that maternal pyrexia was a significant adverse effect.
A 2007 study comparing 800 mg of misoprostol administered rectally with 10 IU of oxytocin administered IM in a
developing country found these 2 agents to be equally effective in minimizing blood loss during the third stage of
labour.31 There was more pyrexia in the misoprostol group,
however.
The systematic review by Joy and colleagues29 compared the
efficacy of misoprostol with that of oxytocin, other
uterotonic agents, and placebo in preventing PPH in the
third stage of labour. Compared with placebo, misoprostol
was associated with a decreased need for additional
uterotonics (OR 0.64; 95% CI 0.46 to 0.90) and an
increased risk of shivering and pyrexia. Oxytocin was superior to misoprostol in preventing blood loss and the need
for additional agents, and the patients had less shivering and
pyrexia. The authors proposed that misoprostol is a reasonable agent for management of the third stage of labour
when other agents are not available for reasons of cost, storage, or difficulty of administration.
There have been no studies to determine the benefit of a
combination of oxytocin and misoprostol compared with
either agent alone.
Recommendation
8. Ergonovine, 0.2 mg IM, and misoprostol, 600 to
800 mg given by the oral, sublingual, or rectal route,
may be offered as alternatives in vaginal deliveries
when oxytocin is not available. (II-1B)
25% to 60% of the fetal–placental circulation is found in the
placental circulation.33,34 Early cord clamping in term newborns results in a decrease of 20 to 40 mL/kg of blood,
which is equivalent to 30 to 35 mg of iron. A delay in clamping, causing increased neonatal blood volume, may lead to
complications such as respiratory distress, neonatal
jaundice, and polycythemia.
Prendiville and colleagues’ meta-analysis espousing the
benefit of AMTSL8 included studies that applied early cord
clamping, controlled traction, and uterotonics before delivery of the placenta. In these studies, early cord clamping was
included as part of controlled traction and was not independently studied to demonstrate a benefit.
A 2004 Cochrane Review by Rabe et al.35 and a prospective
study by Ibrahim et al.36 demonstrated that delaying cord
clamping by 30 to 120 seconds resulted in less need for
transfusion because of anemia (RR 2.01; 95% CI 1.24 to
3.27) and less intraventricular hemorrhage (RR 1.74; 95%
CI 1.08 to 2.81) in nonresuscitated premature infants (< 37
weeks’ gestation).
A systematic review and meta-analysis comparing cord
clamping done early (less than 1 minute after delivery of the
infant) and late (at least 2 minutes after delivery) showed
that late clamping conferred physiological benefit to the
newborn that extended up to 6 months into infancy.37
Advantages included prevention of anemia over the first 3
months of life and enhanced iron stores (weighted mean
difference 19.90; 95% CI 7.67 to 32.13) and ferritin concentration (weighted mean difference 17.89; 95% CI 16.58 to
19.21) for up to 6 months. There was no increase in respiratory distress, defined as tachypnea or grunting. Neonates
were at increased risk of asymptomatic polycythemia (RR
3.82; 95% CI 1.11 to 13.21). There was no significant difference between the early and late groups in bilirubin levels
and proportions of infants receiving phototherapy.
A 2008 Cochrane review included 11 RCTs that compared
the effect on maternal and neonatal outcomes of cord
clamping done early (up to 60 seconds after delivery) and
late (beyond 60 seconds after delivery).38 The results
showed no difference in the incidence of PPH but an
increased incidence of neonatal jaundice requiring
phototherapy, higher newborn hemoglobin levels up to 6
months of age, and higher ferritin levels at 6 months of age
after late clamping.
Management of the Placenta
Recommendations
Timing of cord clamping
9. Whenever possible, delaying cord clamping by at least
60 seconds is preferred to clamping earlier in premature
newborns (< 37 weeks’ gestation) since there is less
intraventricular hemorrhage and less need for transfusion in those with late clamping. (I-A)
Clamping of the umbilical cord is a necessary part of the
third stage of labour. Its timing varies widely throughout
the world, early clamping being the predominant practice in
Western countries.32 Physiological studies have shown that
986
l OCTOBER JOGC OCTOBRE 2009
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
10. For term newborns, the possible increased risk of neonatal jaundice requiring phototherapy must be weighed
against the physiological benefit of greater hemoglobin
and iron levels up to 6 months of age conferred by
delayed cord clamping. (I-C)
Timing of placental delivery
Placental delivery is essential to allow the uterus to contract
and thus reduce blood loss in the third stage of labour. This
process is completed within 5 minutes in 50% of deliveries
and by 15 minutes in 90%. Failure of the placenta to be
delivered in such a timely manner is a well-known risk factor of PPH.39,40
The traditional definition of retained placenta includes failure of placental delivery within 30 to 45 minutes and a
requirement of intervention to assist with delivery. One
study published in 2006 concluded that the risk of PPH
increases if the placenta has not been delivered by 10 minutes, although research is needed to determine if the risk of
PPH can be reduced by intervening at this stage.41
Recommendation
11. There is no evidence that, in an uncomplicated delivery
without bleeding, interventions to accelerate delivery of
the placenta before the traditional 30 to 45 minutes will
reduce the risk of PPH. (II-2C)
Placental cord drainage
Drainage of cord blood has been proposed to assist with
delivery of the placenta.
A 2005 Cochrane review42 included only 2 studies addressing this intervention, which makes it difficult to draw conclusions. The selection criteria for the review were low-risk
vaginal deliveries in which a cord clamped within 30 seconds of delivery and separated was unclamped, which
allowed the blood from the placenta to drain freely. The
measured outcomes included incidence of retained placenta
(at 30 to 45 minutes), manual removal of the placenta, PPH,
length of the third stage of labour, need for blood transfusion, decrease in maternal hemoglobin level, and maternal
pain. The outcomes reported were a decreased incidence of
retained placenta at 30 minutes (RR 0.28; 95% CI 0.10 to
0.73) and a shorter third stage (weighted mean difference
–5.46; 95% CI –8.02 to –2.90) after cord drainage. A major
confounding factor was the lack of use of uterotonics and
the varied definition of a prolonged third stage: from 30 to
45 minutes.
Sharma et al.43 randomly assigned 958 women to either placental cord drainage or controlled traction after administration of 0.2 mg of ergonovine with delivery of the anterior
shoulder and immediate cord clamping. Measured outcomes were PPH and length of the third stage. The third
stage had a mean duration of 3.24 and 3.20 minutes in the
drainage group versus 8.57 and 6.20 minutes in the traction
group in primigravid (P < 0.05) and multigravid (P < 0.05)
women, respectively. There was no significant difference
between the groups in the incidence of blood loss > 500 mL
and the need for transfusion (P > 0.05), and none of the
women had a retained placenta.
The limited number of studies makes it difficult to recommend a change in practice to support routine cord drainage,
but this intervention does appear to reduce the length of the
third stage of labour and the risk of a retained placenta.
More research is required to determine if the length of the
third stage is reduced with routine drainage after the use of
uterotonics and if this intervention reduces the risk of PPH.
Recommendation
12. Placental cord drainage cannot be recommended as a
routine practice since the evidence for a reduction in the
duration of the third stage of labour is limited to women
who did not receive oxytocin as part of the management
of the third stage. There is no evidence that this intervention prevents PPH. (II-1C)
Injection of the umbilical vein
Injection of the umbilical vein has been proposed to assist
in uterine contractions and dehiscence of the placenta from
the uterine wall to effect delivery. If successful, this intervention would avoid manual removal of the placenta, an
invasive procedure with potential complications, including
hemorrhage, infection, and trauma. A 2001 Cochrane
Review44 assessed if injection of various agents would
reduce the need for manual removal of a retained placenta.
The authors derived the following conclusions.
• Saline versus expectant management: no difference
(RR 0.97; 95% CI 0.83 to 1.14).
• Saline plus oxytocin versus expectant management:
nonsignificant reduction in the incidence of manual
removal (RR 0.86; 95% CI 0.72 to 1.01) with the use of
saline plus oxytocin.
• Saline plus oxytocin versus saline: significantly lower
incidence of manual removal of the placenta (RR 0.79;
95% CI 0.69 to 0.91) (number needed to treat: 8; 95%
CI 5 to 20) with the use of saline plus oxytocin.
• Saline plus oxytocin versus plasma expander:
nonsignificantly greater incidence of manual removal of
the placenta (RR 1.34; 95% CI 0.97 to 1.85) with the
use of saline plus oxytocin.
• Saline plus prostaglandin versus saline: significantly
lower incidence of manual removal of the placenta (RR
0.05; 95% CI 0.00 to 0.73) with the use of saline plus
prostaglandin but no difference in the incidence of
blood loss, fever, pain, and oxytocin augmentation.
OCTOBER JOGC OCTOBRE 2009 l
987
SOGC CLINICAL PRACTICE GUIDELINE
Figure 1. Pipingas technique for injection of the intraumbilical vein if the placenta has not separated or
delivered within 45 minutes after delivery of the baby
• Prepare a syringe of misoprostol (800 mg) or oxytocin (50 IU) dissolved in 30 mL of normal saline.
• Insert a size 10 nasogastric suction catheter along the umbilical vein. If resistance is felt, retract the catheter 1 to 2 cm
and advance it further, if possible. If the catheter cannot be advanced further without force, inject the solution in this
position.
• If most of the catheter has been inserted when resistance is felt, indicating that it has reached the placenta, retract it 3 to
4 cm to ensure that the tip is in the umbilical vein and not in a placental branch.
• Connect the syringe to the catheter and inject the solution. Clamp the catheter in situ and record the time of the injection.
• Allow 30 minutes for the placenta to deliver before undertaking further intervention.
• Saline plus prostaglandin versus saline plus oxytocin:
no difference (RR 0.10; 95% CI 0.01 to 1.59).
This review suggests that umbilical vein injection of
uterotonics assists with the third stage of labour but provides no convincing evidence of the benefit; the last 3 conclusions were based on the results of a single small trial. The
authors conclude that umbilical vein injection of oxytocin
may reduce the need for manual removal of a retained placenta, but further investigation is required. There is an
ongoing systematic review to determine if routine injection
of the umbilical vein with a uterotonic within 15 minutes of
birth will affect perinatal and maternal outcomes.45
An RCT compared the effect of intraumbilical vein injection of Syntocinon (synthetic oxytocin; 50 IU in 30 mL of
normal saline), misoprostol (800 mg in 30 mL of normal
saline), or normal saline (30 mL) on the need for manual
removal of the placenta in a prolonged third stage of labour
in 87 low-risk women at term.46 The Pipingas technique
(Figure 1) was used for injection. All the women had
AMTSL with either oxytocin or Syntometrine with delivery
of the anterior shoulder, early cord clamping, and cord traction when signs of placental separation were observed. The
women whose third stage exceeded 30 minutes were randomly assigned to intervention at 45 minutes with 1 of the 3
injections. The trial was stopped when the misoprostol
group had many fewer instances of manual removal of the
placenta (9 of 21 women) compared with the Syntocinon
group (16 of 20 women) and the saline group (7 of 13
women).
Recommendation
13. Intraumbilical cord injection of misoprostol (800 mg) or
oxytocin (10 to 30 IU) can be considered as an alternative
intervention before manual removal of the placenta.
(II-2C)
TREATMENT OF ESTABLISHED PPH
Research has shown that care providers poorly estimate
blood loss7 and consistently underestimate the loss of a
988
l OCTOBER JOGC OCTOBRE 2009
large volume of blood.43 Clinical signs and symptoms
(Table 2) are useful bedside indicators of ongoing blood
loss and will assist clinicians in management. A previously
established plan of action is of great value when preventive
measures have failed. This plan should include aggressive
fluid resuscitation, control of bleeding to minimize loss, and
access to a surgical room and support personnel (Table 4).
The initial goal of management is to determine the cause of
blood loss while instituting resuscitative measures. Evaluation of uterine tone and a complete inspection of the lower
genital tract are required. The goal of resuscitative measures
is to maintain hemodynamic stability and oxygen perfusion
of the tissues. An IV infusion of crystalloid solution should
be instituted, using large-bore tubing, along with oxygen
supplementation. The “ABCs” should be observed and
vital signs, oxygen saturation, and urinary output monitored. A visual assessment of clotting can be done at the
bedside while blood is sent for analysis and matching for
transfusion.
PPH emergencies often occur unexpectedly and, depending
on the volume of deliveries in each institution, may be infrequent. When a situation does not resolve with the usual
interventions, there is a need for more equipment that may
not be readily available when needed. For these reasons,
every obstetric unit should have a readily available tray with
all of the necessary equipment. Since clinicians may rarely
apply these interventions, this equipment should be accompanied by appropriate diagrams illustrating the relevant
anatomy and technique. A previously prepared PPH tray in
a large Canadian birthing centre was used in 1 in 250 Caesarean
sections and 1 in 1000 vaginal deliveries.47
Recommendations
14. For blood loss estimation, clinicians should use clinical
markers (signs and symptoms) rather than a visual
estimation. (III-B)
15. Management of ongoing PPH requires a multidisciplinary
approach that involves maintaining hemodynamic stability while simultaneously identifying and treating the
cause of blood loss. (III-C)
OCTOBER JOGC OCTOBRE 2009 l
Uterine fundus not felt
abdominally OR visible
vaginally
Excess bleeding or
shock shortly after birth,
uterus contracted
Placenta not separated
or partially separated
(with or without
hemorrhage)
Uterus soft and relaxed
Clotting
Uterine
inversion
® Laparotomy:
Uterine rupture
• Treat accordingly with
blood products
Clotting disorder
® Correct inversion in
theatre under general
anaesthesia
• Hysterectomy
• Primary repair
® Repair tears in
perineum, vagina and
cervix
• Gentle curettage
• Manual exploration
• Manual vacuum
aspiration
Incomplete separation
• Intraumbilical vein
injection
• Controlled cord
traction
• Uterotonics
Whole placenta in uterus
Uterotonic drugs
Uterine massage
Directed therapy
Low genital
tract trauma
Retained
placenta
Uterine atony
Assess etiology
If nonsurgical correction
fails, ensure that uterus
remains contracted by
continued oxytocin
infusion
Manual removal
Placenta still retained
• Balloon (condom)
tamponade
• Uterine packing
• External aortic
compression
• Bimanual uterine
compression
Nonsurgical uterine
compression
If bleeding continues
Adapted with permission of the World Health Organization from Postpartum Hemorrhage Technical Consultation Meeting Document55
• Blood grouping
and cross
• Coagulation screen
• Complete blood count
Laboratory tests
• Empty bladder, monitor
urine output
• Monitor BP, P, R
• Crystalloid, isotonic
fluid replacement
• IV line
• Oxygen by mask
• Assess the “ABC”
Resuscitation
Call for help
Initial assessment and
treatment for primary PPH
Table 4. Treatment of PPH
Hysterectomy
Correction via
laparotomy
Surgery
Hysterectomy
Hysterectomy
Partial or complete
removal of placenta
through laparotomy
Placenta still retained
(placenta accreta)
Uterine artery
embolization
• Cho square
• Vertical compression
Hysterectomy
(subtotal or total)
Artery ligation
(uterine, hypogastric)
Compression sutures
• B-Lynch
If bleeding continues
If bleeding continues
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
989
SOGC CLINICAL PRACTICE GUIDELINE
16. All obstetric units should have a regularly checked PPH
emergency equipment tray containing appropriate
equipment. (II-2B)
Uterine Massage and Additional Uterotonic
Administration
Since the most common cause of PPH is uterine atony, the
clinician’s initial efforts should be directed at preventing
ongoing blood loss by performing the initial basic
maneuvres of uterine massage and administering additional
uterotonics, which include the following.
1. Oxytocin
• 10 IU IM. Consider ability of the medication to
reach a uterus with poor tissue perfusion.
• 5 IU IV push
• 20 to 40 IU in 250 mL of normal saline, infused IV
at an hourly rate of 500 to 1000 mL.
2. 15-methyl prostaglandin (carboprost tromethamine
[Hemabate])
• 250 mg IM or intramyometrially
• Can be repeated every 15 minutes to a maximum of
2 mg (8 doses).
• Asthma is a relative contraindication.
3. Carbetocin
• 100 mg IM or IV over 1 minute
• Shown to reduce bleeding due to uterine atony in
Caesarean sections but not low-risk vaginal
deliveries.
4. Misoprostol (off-label use not approved for PPH by
Health Canada)
• 400 to 800 mg. Onset of effects is faster with oral or
sublingual than with rectal administration.
• 800 to 1000 mg. Effects are longer lasting with rectal
than with oral administration.
• Higher incidence of pyrexia with oral than with
rectal administration.
5. Ergonovine
• 0.25 mg IM or IV, can be repeated every 2 hours
• Contraindicated in women with hypertension and
those taking certain drugs (e.g., proteases for HIV
infection).
6. Recombinant activated factor VII
• Has been used in women with massive PPH but in a
limited number of studies, all without
randomization.
• A review by Franchini et al.48 suggests a potential
role, although further research is required to
determine this agent’s role and benefit.
990
l OCTOBER JOGC OCTOBRE 2009
Recommendation
17. Evidence for the benefit of recombinant activated factor VII has been gathered from very few cases of massive
PPH. Therefore this agent cannot be recommended as
part of routine practice. (II-3L)
Tamponade
The quickest method of tamponade is with bimanual compression of the uterus. One hand is placed over the uterus
externally; the other is placed in the vagina to apply pressure
on the lower segment. Consistent compression with the 2
hands results in external compression of the uterus to
reduce blood flow. This can be continued until further measures are taken or assistance arrives.
In the case of uterine atony, the following can be placed
inside the uterus to provide direct compression of the uterine wall and thus decrease blood loss.
• Bakri SOS tamponade balloon catheter
• Sengstaken Blakemore esophageal catheter
• Foley catheter filled with 60 to 80 mL of sterile
solution
• Rusch hydrostatic urologic balloon
• Hydrostatic condom catheter
• Uterine packing
All the above have been reported to be successful for the
temporary control of active bleeding. The insertion technique for a balloon device is relatively simple and requires
the operator to ensure that the entire balloon is positioned
past the cervical canal. Once inserted, the balloon is filled
with sterile solution until there is no further bleeding. After
successful tamponade, continued oxytocin infusion may be
required to maintain uterine tone. Prophylactic antibiotic
therapy should be considered. The balloon can be left in
place for 8 to 48 hours and then gradually deflated and
removed.
Uterine packing requires greater skill and experience to
properly pack the uterus with enough gauze to control
bleeding while avoiding trauma to the uterine wall. Other
disadvantages include risk of infection, unrecognized bleeding with blood soaking the packing material, and the possible need for another surgical procedure to remove the
material.
Recommendation
18. Uterine tamponade can be an efficient and effective
intervention to temporarily control active PPH due to
uterine atony that has not responded to medical
therapy. (III-L)
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
Figure 2. B-Lynch technique for uterine compression sutures
Reproduced from B-Lynch et al52 with permission of the Royal College of Obstetricians and Gynaecologists.
Figure 3. Cho technique for uterine compression sutures
Reproduced from Cho et al53 with permission of the Royal College of Obstetricians and Gynaecologists.
OCTOBER JOGC OCTOBRE 2009 l
991
SOGC CLINICAL PRACTICE GUIDELINE
Radiologic Methods
Percutaneous transcatheter arterial embolization is an
option when there is active bleeding in a hemodynamically
stable woman and before surgical intervention.49 A review
of the literature found success rates of 100% after 49 vaginal deliveries and 89% after 18 Caesarean sections. This
technique preserves the uterus and adnexa and thus fertility.
The procedure requires rapid access to imaging technology
and interventional radiologists, which is not available to all
centres.
Surgical Methods
Ligation of the internal iliac artery was used to control
intraoperative bleeding from cervical cancer before being
applied to obstetric cases.50 A retrospective study found this
technique to be useful for preventing PPH in women at
high risk of hemorrhage and for treating PPH due to uterine
atony or genital tract injury.51 The timing of this intervention is important: it must be done without delay, before
excessive blood loss has occurred. Surgical skill is required
to avoid failure and complications such as damage to other
vascular structures and the ureters.
3. Subtil D, Sommé A, Ardiet E, Depret-Mosser S. [Postpartum hemorrhage:
frequency, consequences in terms of health status, and risk factors before
delivery]. J Gynecol Obstet Biol Reprod (Paris) 2004;33(8 Suppl):4S9–4S16.
4. Ramanathan G, Arulkumaran S. Postpartum haemorrhage. Curr Obstet
Gynaecol 2006;16(1):6–13.
5. Kane TT, el-Kady AA, Saleh S, Hage M, Stanback J, Potter L. Maternal
mortality in Giza, Egypt: magnitude, causes, and prevention. Stud Fam
Plann 1992;23:45–57.
6. Maier RV. Approach to the patient with shock. In: Kasper DL, Braunwald
E, Fauci AS, Hauser SL, Longo DL, Jameson JL, editors. Harrison’s
principles of internal medicine. 16th ed. New York: McGraw-Hill;
2004:1600–6.
7. Bose P, Regan F, Paterson-Brown S. Improving the accuracy of estimated
blood loss at obstetric haemorrhage using clinical reconstructions. BJOG
2006;113:919–24.
8. Prendiville WJ, Elbourne D, McDonald S. Active versus expectant
management in the third stage of labour. Cochrane Database Syst Rev
2000;(3):CD000007.
9. International Confederation of Midwives, International Federation of
Gynaecologists and Obstetricians. Joint statement: management of the
third stage of labour to prevent post-partum haemorrhage. J Midwifery
Womens Health 2004;49:76–77.
10. World Health Organization. Recommendations for the Prevention of
Postpartum Haemorrhage. Geneva: WHO; 2007.
11. Khan GQ, John IS, Wani S, Doherty T, Sibai BM. Controlled cord traction
versus minimal intervention techniques in delivery of the placenta: a
randomized controlled trial. Am J Obstet Gynecol 1997;177(4):770–4.
Uterine compression sutures, described by B-Lynch52 (Figure 2) and Cho53 (Figure 3), have the benefit of preserving
the uterus. Both techniques involve external compression
of the uterus to control bleeding, followed by application of
sutures into and over the uterus. The sutures are tied down
to maintain uterine compression and control further bleeding. A hysterotomy at the lower segment is required to
ensure that there are no retained products that would prevent compression of the uterus and subsequent failure of
pregnancy.
12. McDonald S, Abbott JM, Higgins SP. Prophylactic ergometrine–oxytocin
versus oxytocin for the third stage of labour. Cochrane Database Syst Rev
2004;(1):CD000201.
Peripartum hysterectomy is indicated when massive hemorrhage has not responded to previous interventions and
requires a surgical intervention familiar to surgeons. Indications include abnormal placentation (previa, accreta), atony,
trauma, rupture, and sepsis. The disadvantage of
peripartum hysterectomy is the loss of fertility in women
who wish to continue childbearing.
16. Begley C. A comparison of ‘active’ and ‘physiological’ management of the
third stage of labour. Midwifery 1990;6:3–17.
Recommendation
19. Surgical techniques such as ligation of the internal iliac
artery, compression sutures, and hysterectomy should be
used for the management of intractable PPH unresponsive to medical therapy. (III-B)
REFERENCES
1. AbouZahr C. Global burden of maternal death and disability. Br Med Bull
2003;67:1–11.
2. Reynders FC, Senten L, Tjalma W, Jacquemyn Y. Postpartum hemorrhage:
practical approach to a life-threatening complication. Clin Exp Obstet
Gynecol 2006;33:81–4.
992
l OCTOBER JOGC OCTOBRE 2009
13. Cotter A, Ness A, Tolosa J. Prophylactic oxytocin for the third stage of
labour. Cochrane Database Syst Rev 2001;(4):CD001808.
14. Nordstrom L, Fogelstam K, Fridman G, Larsson A, Rydhstroem H.
Routine oxytocin in the third stage of labour: a placebo controlled
randomised trial. Br J Obstet Gynaecol 1997;104:781–6.
15. Jackson KW Jr, Allbert JR, Schemmer GK, Elliot M, Humphrey A, Taylor J.
A randomized controlled trial comparing oxytocin administration before
and after placental delivery in the prevention of postpartum hemorrhage.
Am J Obstet Gynecol. 2001 Oct;185(4):873–7.
17. Davies GA, Tessier JL, Woodman MC, Lipson A, Hahn PM. Maternal
hemodynamics after oxytocin bolus compared with infusion in the third
stage of labor: a randomized controlled trial. Obstet Gynecol
2005;105:294–9.
18. Thomas JS, Koh SH, Cooper GM. Hemodynamic effects of oxytocin given
as IV bolus or infusion on women undergoing caesarean section. Br J
Anaesth 2007;98;116–9.
19. Svanström MC, Biber B, Hanes M, Johansson G, Näslund U, Balfors EM.
Signs of myocardial ischemia after injection of oxytocin: a randomized
double-blind comparison of oxytocin and methylergometrine during
caesarean section. Br J Anaesth 2008;100:683–9.
20. Dansereau J, Joshi AK, Helewa ME, Doran TA, Lange IR, Luther ER, et al.
Double-blind comparison of carbetocin versus oxytocin in prevention of
uterine atony after cesarean section. Am J Obstet Gynecol 1999;180(3 Pt
1):670–6.
21. Sweeney G, Holbrook AM, Levine M, Yip M, Alfredsson K, Cappi S, et al.
Pharmacokinetics of a long-acting oxytocin analogue, in non-pregnant
women. Curr Ther Res 1990;47:528–40.
22. Boucher M, Nimrod CA, Tawagi GF, Meeker TA, Rennicks White RE,
Varin J. Comparison of carbetocin and oxytocin for the prevention of
Active Management of the Third Stage of Labour: Prevention and Treatment of Postpartum Hemorrhage
postpartum hemorrhage following vaginal delivery: a double-blind
randomized trial. J Obstet Gynaecol Can 2004;26:481–8.
23. Su LL, Chong YS, Samuel M. Oxytocin agonists for preventing postpartum
hemorrhage. Cochrane Database Syst Rev 2007;(3):CD005457.
24. Leung SW, Ng PS, Wong WY, Cheung TH. A randomized trial of
carbetocin versus Syntometrine in the management of the third stage of
labour. BJOG 2006;113:1459–64.
40. Combs CA, Laros RK. Prolonged third stage of labor; morbidity and risk
factors. Obstet Gynecol 1991;77:863–7.
41. Magann EF, Doherty DA, Briery CM, Niederhauser A, Morrison JC.
Timing of placental delivery to prevent post-partum haemorrhage: lessons
learned from an abandoned randomised clinical trial. Aust N Z J Obstet
Gynaecol 2006;46:549–51.
25. El-Refaey H, O’Brien P, Morafa W, Walder J, Rodeck C. Misoprostol for
third stage of labour [letter]. Lancet 1996;347:1257.
42. Soltani H, Dickinson F, Symonds I. Placental cord drainage after
spontaneous vaginal delivery as part of the management of the third stage
of labour. Cochrane Database Syst Rev 2005;(4):CD004665.
26. Hofmeyr GJ, Walraven G, Gülmezoglu AM, Maholwana B, Alfirevic Z,
Villar J. Misoprostol to treat postpartum haemorrhage: a systematic review.
BJOG 2005;112:547–53.
43. Sharma JB, Pundir P, Malhotra M, Arora R. Evaluation of placental drainage
as a method of placental delivery in vaginal deliveries. Arch Gynecol Obstet
2005;271:343–5.
27. Gülmezoglu AM, Forna F, Villar J, Hofmeyr GJ. Prostaglandins for
prevention of postpartum haemorrhage. Cochrane Database Syst Rev
2004;(1):CD000494.
44. Carroli G, Bergel E. Umbilical vein injection for management of retained
placenta. Cochrane Database Syst Rev 2001;(4):CD001337.
28. Villar J, Gülmezoglu AM, Hofmeyr GJ, Forna F. Systematic review of
randomized controlled trials of misoprostol to prevent postpartum
hemorrhage. Obstet Gynecol 2002;100:1301–12.
29. Joy SD, Sanchez-Ramos L, Kaunitz AM. Misoprostol use during the third
stage of labor. Int J Gynaecol Obstet 2003;82:143–52.
30. Gülmezoglu AM, Villar J, Ngoc NT, Piaggio G, Carroli G, Adetoro L, et al.
WHO multicentre randomised trial of misoprostol in the management of
the third stage of labour. Lancet 2001;358:689–95.
31. Parsons SM, Walley RL, Crane JMG, Matthews K, Hutchens D. Rectal
misoprostol versus oxytocin in the management of the third stage of labour.
J Obstet Gynaecol Can 2007;29:711–8.
32. Morley G. Cord closure: Can hasty clamping injure the newborn? OBG
Manage 1998;July:29–36.
33. Dixon LR. The complete blood count: physiologic basis and clinical usage.
J Perinat Neonatal Nurs 1997;11:1–18.
34. Yao AC, Moinian M, Lind J. Distribution of blood between infant and
placenta after birth. Lancet 1969;2:871–3.
35. Rabe H, Reynolds G, Diaz-Rossello J. Early versus delayed umbilical cord
clamping in preterm infants. Cochrane Database Syst Rev
2004;(4):CD003248.
45. Nardin JM, Carroli G, Weeks a.d., Mori R. Umbilical vein injection for the
routine management of third stage of labour [Protocol]. Cochrane Database
Syst Rev 2006;(4):CD006176.
46. Rogers MS, Yuen PM, Wong S. Avoiding manual removal of placenta:
evaluation of intra-umbilical injection of uterotonics using the Pipingas
technique for management of adherent placenta. Acta Obstet Gynecol
2007;86:48–54.
47. Baskett TF. Surgical management of severe obstetrical hemorrhage:
experience with an obstetrical hemorrhage equipment tray. J Obstet
Gynaecol Can 2004;26:805–8.
48. Franchini M, Lippi G, Franchi M. The use of recombinant activated factor
VII in obstetric and gynaecological haemorrhage. BJOG 2007;114:8–15.
49. Vedantham S, Goodwin SC, McLucas B, Mohr G. Uterine artery
embolization: an underused method of controlling pelvic hemorrhage. Am J
Obstet Gynecol 1997;176:938–48.
50. Kelly HA. Ligation of both internal iliac arteries for hemorrhage in
hysterectomy for carcinoma uteri. Bull Johns Hopkins Hosp 1984;5:53.
51. Joshi V, Otiv SR, Majumder R, Nikam YA, Shrivastava M. Internal iliac
artery ligation for arresting postpartum haemorrhage. BJOG
2007;114:356–61.
36. Ibrahim HM, Krouskop RW, Lewis DF, Dhanireddy R. Placental
transfusion: umbilical cord clamping and preterm infants. J Perinatol
2000;20:351–4.
52. B-Lynch C, Coker A, Lawal AH, Abu J, Cowen MJ. The B-Lynch surgical
technique for the control of massive postpartum haemorrhage: An
alternative to hysterectomy? Five cases reported. Br J Obstet Gynaecol
1997;104:372–5.
37. Hutton EK, Hassan ES. Late vs early clamping of the umbilical cord in
full-term neonates: systematic review and meta-analysis of controlled trials.
JAMA 2007;297:1241–52.
53. Cho JH, Jun HS, Lee CN. Hemostatic suturing technique for uterine
bleeding during cesarean delivery. Obstet Gynecol 2000;96(1):129–31.
38. McDonald SJ, Middleton P. Effect of timing of umbilical cord clamping of
term infants on maternal and neonatal outcomes. Cochrane Database Syst
Rev 2008;(2):CD004074.
54. Woolf SH, Battista RN, Angerson GM, Logan AG, Eel W. Canadian Task
Force on Preventive Health Care. New grades for recommendations from
the Canadian Task Force on Preventive Health Care. CMAJ
2003;169(3):207–8.
39. Dombrowski MP, Bottoms SF, Saleh AA, Hurd WW, Romero R. Third
stage of labor: analysis of duration and clinical practice. Am J Obstet
Gynecol 1995;172:1279–84.
55. Mathai M, Gulmezoglu AM. Postpartum haemorrhage and retained
placenta. WHO guideline. Geneva: World Health Organization;2009.
OCTOBER JOGC OCTOBRE 2009 l
993